OneSource Specialty Pharma Navigates Q3 FY26 Headwinds, Reaffirms FY28 Vision
OneSource Specialty Pharma Limited, a prominent player in the CDMO sector, reported a challenging third quarter for fiscal year 2026, with its financial performance significantly impacted by external factors. The company's revenue for Q3 FY26 stood at INR 290.3 crore, marking a 26% decline year-on-year. This shortfall was primarily attributed to unforeseen delays in customer approvals for semaglutide products in Canada, which prolonged the transition from Master Service Agreements (MSAs) to Commercial Supply Agreements (CSAs). Consequently, the company's EBITDA also saw a substantial reduction, falling to INR 17.3 crore, resulting in a significant 3,018 basis point contraction in EBITDA margins compared to the previous year. Despite these immediate headwinds, management has expressed strong confidence in its long-term trajectory, reaffirming its ambitious FY28 guidance.
The subdued quarterly performance was largely a function of the DDC (Drug-Device Combinations) business, which typically forms a major part of the company's revenue and profit. The deferral of Canadian approvals meant that anticipated revenues from this high-margin segment could not be recognized. This situation, combined with a largely fixed cost base, led to unfavorable operating leverage. However, the underlying demand for OneSource's offerings remains robust, with order books continuing to trend upwards across various markets, including India and other emerging economies that are opening up for semaglutide. The company's strategy to prioritize capacities for commercial sales over new MSAs, while impacting short-term revenue, is a deliberate choice aimed at maximizing long-term economic benefits from contractual obligations.
Strategic Initiatives and Capacity Expansion Drive Future Growth
OneSource is not merely reacting to market conditions but is proactively shaping its future through strategic investments and capacity expansions. The company has committed 100 million (approximately INR 876.7 crore) for the flagship site is 75% committed and progressing on schedule, with significant additional capacities expected to come online by H2 FY27.
In the nascent biologics segment, OneSource is witnessing strong interest. The company has onboarded another global biosimilar player, a US-based major with a pipeline of over five biosimilars. The Request for Proposal (RFP) funnel for biologics has grown fourfold compared to FY25, driven by favorable USFDA guidelines easing biosimilar development pathways and the BIOSECURE Act, which boosts opportunities for Indian CDMOs by strengthening supply chain security. These tailwinds, coupled with expiring patents on blockbuster biologics, are unlocking unprecedented scale for biosimilar competition, positioning OneSource for substantial growth.
Operationally, the company is strengthening its commercial launch readiness at the flagship DDC facility, having added over 300 full-time equivalent (FTE) employees in FY26. This expansion is vital for managing increased operational demands and ensuring a smooth ramp-up of commercial supplies. Furthermore, OneSource has secured NDA approval for its first oncology soft gelatin product, a branded and unique offering, and has partnered with a top 10 US generics major for its launch in the next quarter. This diversifies the company's specialty offerings and revenue streams. While a four-month shutdown at the Bangalore general injectable site is planned to upgrade lyophilization capacities and add new capabilities for specialty injectables, this short-term disruption is expected to yield long-term benefits in terms of enhanced capacity and competitiveness.
Financial Prudence and Market Outlook
Despite the revenue challenges, OneSource has demonstrated financial prudence. The company has fully provided for the impact of the new wage code in its Q3 financials, reflecting a conservative accounting approach. On the treasury front, the effective interest rate has decreased to below 9%, a 200 basis point reduction year-on-year, thanks to two rating upgrades and strong relationships with global and Indian bankers. This will contribute to lower finance costs going forward. The company's net debt-to-EBITDA is projected to be less than 1.5x by FY28, with the base business potentially becoming debt-free.
Management's decision to be flexible with take-or-pay contracts for key partners, especially those facing approval delays, underscores a long-term partnership philosophy. This approach aims to build trust and secure extended contractual obligations, ensuring mutual benefit as partners gain market share. While the Indian market is not a primary focus due to severe competitive intensity, OneSource's products will be available through partners. The company anticipates a flurry of approvals in emerging markets around early April 2026, following the launch of products in India, which will enable the issuance of Certificates of Pharmaceutical Product (COPPs).
Reaffirming the Vision
OneSource Specialty Pharma Limited's Q3 FY26 results reflect a period of strategic navigation through temporary market and regulatory headwinds. The company's unwavering commitment to its FY28 guidance of 160 million in EBITDA, along with a targeted FY25-28 revenue CAGR of over 30% and a steady-state EBITDA margin of approximately 40%, highlights a clear long-term vision. By diligently expanding capacity, strengthening its biologics pipeline, and maintaining financial discipline, OneSource is positioning itself for substantial growth and sustained value creation in the evolving CDMO landscape. The current quarter, though subdued, is viewed as a transitory phase, with the company building readiness for significant commercial uplift starting in FY27.
Frequently Asked Questions
Did your stocks survive the war?
See what broke. See what stood.
Live Q1 Earnings Tracker